vida: extract claims from 2026-05-05-npr-glp1-eating-disorders-not-well-understood

- Source: inbox/queue/2026-05-05-npr-glp1-eating-disorders-not-well-understood.md
- Domain: health
- Claims: 2, Entities: 0
- Enrichments: 4
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/glp1-adolescent-eating-disorder-risk-amplified-by-developmental-timing.md

@@ -10,9 +10,16 @@ agent: vida
 sourced_from: health/2025-xx-pmc-glp1-eating-disorders-double-edged-sword.md
 scope: causal
 sourcer: PMC / Journal of Clinical Medicine
-related: ["glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive", "glp1-social-media-cosmetic-misuse-creates-eating-disorder-pathway"]
+related: ["glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive", "glp1-social-media-cosmetic-misuse-creates-eating-disorder-pathway", "glp1-adolescent-eating-disorder-risk-amplified-by-developmental-timing"]
 ---
 
 # Adolescents face compounded GLP-1 eating disorder risk because ED prevalence peaks during adolescence while social media exposure is highest
 
 The review identifies adolescents as the highest-risk population for GLP-1-induced eating disorder harm through a developmental timing mechanism. Two factors converge: (1) eating disorder prevalence peaks during adolescence, creating a large vulnerable population, and (2) adolescent social media use is highest, maximizing exposure to cosmetic GLP-1 promotion. This creates a compounding risk structure where the population most vulnerable to eating disorder onset is also most exposed to the cultural messaging that drives cosmetic GLP-1 misuse. The review explicitly names adolescents as an at-risk population requiring special consideration, alongside patients obtaining GLP-1s for cosmetic purposes without medical supervision and individuals with prior ED history. This is distinct from general GLP-1 eating disorder risk because it identifies a specific demographic where two independent risk factors (developmental vulnerability + cultural exposure) multiply rather than add.
+
+
+## Extending Evidence
+
+**Source:** NPR investigation, 2026-02-04
+
+NPR identifies 'men with eating disorders (underdiagnosed)' as a specific at-risk group, extending the adolescent developmental timing concern to adult populations where eating disorders are systematically under-detected. This suggests the amplification mechanism operates wherever baseline detection is poor, not just in adolescents—underdiagnosis creates vulnerability regardless of age.

domains/health/glp1-atypical-anorexia-invisible-to-bmi-screening.md

@@ -0,0 +1,19 @@
+---
+type: claim
+domain: health
+description: Atypical anorexics meet full diagnostic criteria for anorexia nervosa despite normal or elevated BMI, making them appear as ideal GLP-1 candidates to prescribers using weight-based screening alone
+confidence: experimental
+source: Dr. Kim Dennis (eating disorder specialist), NPR investigation
+created: 2026-05-05
+title: GLP-1 prescribing creates systematic risk for atypical anorexia patients because BMI-based eligibility screening cannot detect restrictive psychopathology in overweight individuals
+agent: vida
+sourced_from: health/2026-05-05-npr-glp1-eating-disorders-not-well-understood.md
+scope: structural
+sourcer: "NPR (@NPRHealth)"
+supports: ["glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive"]
+related: ["glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge", "glp1-pre-treatment-eating-disorder-screening-recommended-not-required", "glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive", "glp1-social-media-cosmetic-misuse-creates-eating-disorder-pathway", "glp1-anorexia-nervosa-evidence-absent-despite-pharmacovigilance-signal"]
+---
+
+# GLP-1 prescribing creates systematic risk for atypical anorexia patients because BMI-based eligibility screening cannot detect restrictive psychopathology in overweight individuals
+
+Dr. Kim Dennis identifies a structural screening gap: patients with atypical anorexia nervosa meet full diagnostic criteria for restrictive eating disorders despite having normal or elevated BMI. To a prescriber using standard weight-based eligibility criteria, these patients appear as ideal GLP-1 candidates—overweight individuals seeking medically supervised weight loss. However, they have active restrictive psychopathology that GLP-1s would amplify. The NPR piece quotes Dennis specifically raising concern for 'atypical anorexics' who 'appear like ideal GLP-1 candidates to an unaware prescriber.' This creates a population-specific harm pathway that standard BMI screening cannot detect. The mechanism is invisibility: the very criterion that makes someone eligible (elevated BMI) masks the psychological contraindication (active restriction). This is distinct from general eating disorder risk—it's a specific population where the eligibility criterion and the risk factor are structurally confounded.

domains/health/glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive.md

@@ -31,3 +31,10 @@ This review establishes that GLP-1 receptor agonists create opposing clinical ou
 **Source:** NBC News 2024-08-15
 
 Clinicians describe progression from beneficial appetite suppression to pathological restriction, with 'atypical anorexia nervosa' pattern emerging. Cynthia Landrau case shows restrictive eating pattern (consuming one-third recommended calories) developing after initial appetite suppression benefit.
+
+
+## Extending Evidence
+
+**Source:** Dr. Samantha DeCaro, NPR 2026-02-04
+
+Dr. DeCaro notes eating disorders involve 'emotional, relational, and biological drivers' and that 'weight loss alone doesn't address underlying psychology.' This provides clinical expert framing for why restrictive subtypes are harmed—GLP-1s address weight but amplify the psychological restriction that defines the disorder. The mechanism is that pharmacological appetite suppression reinforces rather than treats the core psychopathology in restrictive disorders.

domains/health/glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge.md

@@ -38,3 +38,10 @@ ANAD's epistemic honesty is striking: 'We simply do not know if these medication
 **Source:** NBC News 2024-08-15
 
 Collaborative of Eating Disorders Organizations calling for mandatory screening before prescribing, indicating current practice lacks standardized pre-treatment ED assessment. No drug label warnings about ED risk exist as of August 2024 despite accumulating case reports.
+
+
+## Extending Evidence
+
+**Source:** Dr. Samantha DeCaro, NPR 2026-02-04
+
+Dr. Samantha DeCaro provides expert framing that GLP-1s are 'potentially more harmful' than prior weight-loss drugs specifically because they 'make it harder for people to nourish themselves regularly, or tune into their natural hunger cues.' This identifies the pharmacological mechanism (appetite suppression intensity) that makes screening gaps more consequential for GLP-1s than for prior weight-loss medications. The harm isn't just from missing eating disorders—it's that GLP-1s are uniquely powerful at amplifying restrictive pathology.

domains/health/glp1-harm-mediated-by-cultural-weight-stigma-context.md

@@ -0,0 +1,19 @@
+---
+type: claim
+domain: health
+description: Expert consensus frames GLP-1 safety as interaction between pharmacology and cultural environment, with weight pressure and stigma determining who is harmed
+confidence: experimental
+source: Robyn Pashby (OAC board), Dr. Samantha DeCaro, NPR investigation
+created: 2026-05-05
+title: GLP-1 harm risk is mediated by cultural weight stigma context not just pharmacological properties because the same drug produces different outcomes in populations with different weight-related trauma exposure
+agent: vida
+sourced_from: health/2026-05-05-npr-glp1-eating-disorders-not-well-understood.md
+scope: causal
+sourcer: "NPR (@NPRHealth)"
+supports: ["medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm"]
+related: ["glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive", "glp1-adolescent-eating-disorder-risk-amplified-by-developmental-timing", "glp1-social-media-cosmetic-misuse-creates-eating-disorder-pathway", "glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations"]
+---
+
+# GLP-1 harm risk is mediated by cultural weight stigma context not just pharmacological properties because the same drug produces different outcomes in populations with different weight-related trauma exposure
+
+Robyn Pashby from the Obesity Action Coalition frames the core tension: 'We need to hold two truths: That GLP-1s are legitimate evidence-based treatments for obesity, but that they also sit inside our culture, which has intense weight pressure, weight stigma and eating disorder risk.' This positions harm not as purely pharmacological but as culturally mediated. Dr. DeCaro reinforces this by noting eating disorders involve 'emotional, relational, and biological drivers'—weight loss alone doesn't address underlying psychology. The NPR piece identifies specific at-risk groups defined by cultural exposure: 'those with prior body-weight trauma/bullying' and people obtaining drugs online without clinical evaluation. The mechanism is that cultural weight stigma creates psychological vulnerability, and GLP-1s amplify that vulnerability in susceptible individuals. This explains why the same drug can be therapeutic for metabolic disease patients but harmful for individuals with weight-related trauma—the pharmacology is constant, but the cultural context differs. This is a social determinants of health argument applied to pharmacological harm.

domains/health/glp1-pre-treatment-eating-disorder-screening-recommended-not-required.md

@@ -38,3 +38,10 @@ VigiBase analysis quantifies eating disorder signal magnitude at aROR 4.17-6.80
 **Source:** ANAD 2026 clinical guidance
 
 ANAD (the authoritative US professional society for eating disorders) formalizes the screening gap: they recommend tri-specialist evaluation (physician + therapist + dietitian all versed in both GLP-1s and eating disorders) before prescribing, but acknowledge this has zero regulatory force. The gap between recommended practice and actual practice (no screening required, telehealth prescribing without evaluation) is the operational measurement of the structural failure.
+
+
+## Supporting Evidence
+
+**Source:** NPR investigation, 2026-02-04
+
+NPR investigation documents that 'easy online access with little screening creates vulnerability in susceptible populations' and identifies specific at-risk groups including 'people obtaining online without clinical evaluation.' This confirms that the recommended-not-required gap enables systematic under-screening, particularly in telehealth channels where the structural capacity for screening is lowest.

inbox/archive/health/2026-05-05-npr-glp1-eating-disorders-not-well-understood.md

@@ -7,10 +7,13 @@ date: 2026-02-04
 domain: health
 secondary_domains: []
 format: article
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-05
 priority: high
 tags: [glp-1, eating-disorders, semaglutide, wegovy, anorexia, atypical-anorexia, screening]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content